11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity

Katherine A Hughes, Scott P Webster, Brian R Walker

Research output: Contribution to journalLiterature reviewpeer-review

Abstract / Description of output

Glucocorticoids such as cortisol are important regulators of fuel metabolism during starvation and stress. Chronic glucocorticoid excess induces obesity with multiple features of the metabolic syndrome.Objective: In this article, we review the importance of glucocorticoids in metabolic syndrome and the approaches that have been explored to reduce glucocorticoid action as the basis for novel therapy of Type 2 diabetes and obesity. Method: We focus on the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), which amplifies glucocorticoid concentrations in key metabolic tissues including liver and adipose tissue. Results/conclusion: Several 11 beta-HSD1 inhibitors are in late preclinical or early clinical development and we review here the properties of the class leaders and their potential as the next generation of drugs with multiple benefits in metabolic syndrome.
Original languageEnglish
Pages (from-to)481-96
Number of pages16
JournalExpert opinion on investigational drugs
Issue number4
Publication statusPublished - Apr 2008


Dive into the research topics of '11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity'. Together they form a unique fingerprint.

Cite this